NVST:NYSEEnvista Holdings Corporation Analysis
Data as of 2026-06-02 - not real-time
$23.37
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Envista delivered a solid first‑quarter performance, posting revenue growth well above the prior year and beating consensus earnings expectations. The company’s non‑GAAP earnings per share came in ahead of estimates, reinforcing the strength of its operating margins. Cash generation remains robust, with operating cash flow comfortably covering capital needs and leaving ample free cash flow. The balance sheet shows a comfortable cash cushion relative to its debt load, and the recent buyback authorization adds further financial flexibility. Technical indicators point to a neutral trend, with the short‑term average below the medium‑term average and momentum indicators suggesting modest oversold pressure.
Despite the recent price being below the discounted cash‑flow estimate, the stock trades at a price‑to‑earnings multiple that is markedly higher than the sector average, indicating a valuation tension between growth expectations and current pricing. Forward earnings multiples have compressed, hinting at improving valuation as earnings accelerate. The upside potential implied by the fair‑value model, combined with a strong earnings beat, supports a bullish outlook, while elevated beta and high recent volatility flag heightened market risk. Overall, the fundamentals and earnings momentum outweigh the valuation concerns, making the stock an attractive candidate for investors with a medium to long‑term horizon.
Despite the recent price being below the discounted cash‑flow estimate, the stock trades at a price‑to‑earnings multiple that is markedly higher than the sector average, indicating a valuation tension between growth expectations and current pricing. Forward earnings multiples have compressed, hinting at improving valuation as earnings accelerate. The upside potential implied by the fair‑value model, combined with a strong earnings beat, supports a bullish outlook, while elevated beta and high recent volatility flag heightened market risk. Overall, the fundamentals and earnings momentum outweigh the valuation concerns, making the stock an attractive candidate for investors with a medium to long‑term horizon.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Recent earnings beat supports price stability
- Technical indicators show neutral momentum
- Support level near current price
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Strong revenue growth trajectory
- Discounted cash‑flow upside potential
- Improving forward earnings multiple
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- Sustainable cash flow generation
- Strategic product portfolio in dental market
- Management’s commitment to shareholder returns via buybacks
Key Metrics & Analysis
Financial Health
Revenue Growth14.40%
Profit Margin2.41%
P/E Ratio57.0
ROE2.21%
ROA3.01%
Debt/Equity51.61
P/B Ratio1.2
Op. Cash Flow$272.1M
Free Cash Flow$216.3M
Industry P/E27.3
Technical Analysis
TrendNeutral
RSI37.7
Support$22.54
Resistance$29.52
MA 20$24.08
MA 50$25.41
MA 200$23.26
MACDBullish
VolumeStable
Fear & Greed Index92.59
Valuation
Fair Value$28.95
Target Price$29.85
Upside/Downside27.71%
GradeUndervalued
TypeGrowth
Risk Assessment
Beta1.55
Volatility37.74%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.